Key insights
- Novo Nordisk launched a higher dose of Wegovy in the US at a competitive price, expanding access through telehealth partnerships and restricting compounded competitors. This strategic move could significantly impact future earnings, with the May 5th report being critical. The increased efficacy and controlled distribution may lead to higher market share and revenue, positively influencing US equity markets, particularly in the healthcare sector.
Novo Nordisk launched Wegovy HD (7.2 mg) in the U.S., a 3× increase from the prior 2.4 mg dose, delivering ~20.7–21% weight loss versus ~17–18% previously. The drug is priced at $399/month cash, below Lilly’s $449 Zepbound, with insured patients paying as little as $25/month.
The company also partnered with Hims & Hers and other telehealth platforms to expand access, with GLP-1 offerings starting around $149/month. At the same time, Novo introduced subscription pricing ($249–$329/month) and moved to restrict non-FDA compounded competitors, tightening control over distribution and pricing.
The pill is out now and more people should know about it
The next earnings should be critical on May 5th